CyBorD-DARA is potent initial induction for MM and enhances ADCP : initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study
© 2019 by The American Society of Hematology..
Daratumumab (DARA) has shown impressive activity in combination with other agents for the treatment of multiple myeloma (MM). We conducted a phase 1b study to assess the safety and preliminary efficacy, as well as potential mechanisms of action, of DARA (16 mg/kg) in combination with a weekly schedule of subcutaneous bortezomib (1.3-1.5 mg/m2), cyclophosphamide (150-300 mg/m2), and dexamethasone (40 mg) (CyBorD DARA) as initial induction before autologous stem cell transplantation (ASCT). Eligible patients were ≤70 years of age with untreated MM requiring treatment and who lacked significant comorbidities. A total of 18 patients were enrolled. Their median age was 56 years (range, 32-66 years), and all patients had Eastern Cooperative Oncology Group performance status ≤1. The International Staging System stages were I, II, and III in 78%, 17%, and 6% of patients, respectively; 28% of patients had high-risk genetic features. There was no dose-limiting toxicity, and the incidence of grade 3 or 4 infection or neutropenia was <10%. On an intention-to-treat basis, 94% achieved ≥very good partial response with ≥complete response in 44% of patients. Among 14 of 15 patients who underwent ASCT and were evaluable for response, all 14 achieved at least very good partial response, with 8 (57%) of 14 achieving complete response. After ASCT, 10 (83%) of 12 patients in whom minimal residual disease analysis was possible were negative at a sensitivity of 10-5 (56% on intention-to-treat/whole study population) according to next-generation sequencing. Flow cytometry analysis of patient samples indicated CyBorD DARA induced activation of macrophage-mediated antibody-dependent cellular phagocytosis. This trial was registered at www.clinicaltrials.gov as #NCT02955810.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
Blood advances - 3(2019), 12 vom: 25. Juni, Seite 1815-1825 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
O'Dwyer, M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.06.2020 Date Revised 15.06.2020 published: Print ClinicalTrials.gov: NCT02955810 Citation Status MEDLINE |
|---|
| doi: |
10.1182/bloodadvances.2019000010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM298177811 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM298177811 | ||
| 003 | DE-627 | ||
| 005 | 20231225093605.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2019000010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0993.xml |
| 035 | |a (DE-627)NLM298177811 | ||
| 035 | |a (NLM)31201169 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a O'Dwyer, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CyBorD-DARA is potent initial induction for MM and enhances ADCP |b initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.06.2020 | ||
| 500 | |a Date Revised 15.06.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT02955810 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 by The American Society of Hematology. | ||
| 520 | |a Daratumumab (DARA) has shown impressive activity in combination with other agents for the treatment of multiple myeloma (MM). We conducted a phase 1b study to assess the safety and preliminary efficacy, as well as potential mechanisms of action, of DARA (16 mg/kg) in combination with a weekly schedule of subcutaneous bortezomib (1.3-1.5 mg/m2), cyclophosphamide (150-300 mg/m2), and dexamethasone (40 mg) (CyBorD DARA) as initial induction before autologous stem cell transplantation (ASCT). Eligible patients were ≤70 years of age with untreated MM requiring treatment and who lacked significant comorbidities. A total of 18 patients were enrolled. Their median age was 56 years (range, 32-66 years), and all patients had Eastern Cooperative Oncology Group performance status ≤1. The International Staging System stages were I, II, and III in 78%, 17%, and 6% of patients, respectively; 28% of patients had high-risk genetic features. There was no dose-limiting toxicity, and the incidence of grade 3 or 4 infection or neutropenia was <10%. On an intention-to-treat basis, 94% achieved ≥very good partial response with ≥complete response in 44% of patients. Among 14 of 15 patients who underwent ASCT and were evaluable for response, all 14 achieved at least very good partial response, with 8 (57%) of 14 achieving complete response. After ASCT, 10 (83%) of 12 patients in whom minimal residual disease analysis was possible were negative at a sensitivity of 10-5 (56% on intention-to-treat/whole study population) according to next-generation sequencing. Flow cytometry analysis of patient samples indicated CyBorD DARA induced activation of macrophage-mediated antibody-dependent cellular phagocytosis. This trial was registered at www.clinicaltrials.gov as #NCT02955810 | ||
| 650 | 4 | |a Clinical Trial, Phase I | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Alkylating |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Hormonal |2 NLM | |
| 650 | 7 | |a Proteasome Inhibitors |2 NLM | |
| 650 | 7 | |a daratumumab |2 NLM | |
| 650 | 7 | |a 4Z63YK6E0E |2 NLM | |
| 650 | 7 | |a Bortezomib |2 NLM | |
| 650 | 7 | |a 69G8BD63PP |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 700 | 1 | |a Henderson, R |e verfasserin |4 aut | |
| 700 | 1 | |a Naicker, S D |e verfasserin |4 aut | |
| 700 | 1 | |a Cahill, M R |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, P |e verfasserin |4 aut | |
| 700 | 1 | |a Mykytiv, V |e verfasserin |4 aut | |
| 700 | 1 | |a Quinn, J |e verfasserin |4 aut | |
| 700 | 1 | |a McEllistrim, C |e verfasserin |4 aut | |
| 700 | 1 | |a Krawczyk, J |e verfasserin |4 aut | |
| 700 | 1 | |a Walsh, J |e verfasserin |4 aut | |
| 700 | 1 | |a Lenihan, E |e verfasserin |4 aut | |
| 700 | 1 | |a Kenny, T |e verfasserin |4 aut | |
| 700 | 1 | |a Hernando, A |e verfasserin |4 aut | |
| 700 | 1 | |a Hirakata, G |e verfasserin |4 aut | |
| 700 | 1 | |a Parker, I |e verfasserin |4 aut | |
| 700 | 1 | |a Kinsella, E |e verfasserin |4 aut | |
| 700 | 1 | |a Gannon, G |e verfasserin |4 aut | |
| 700 | 1 | |a Natoni, A |e verfasserin |4 aut | |
| 700 | 1 | |a Lynch, K |e verfasserin |4 aut | |
| 700 | 1 | |a Ryan, A E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g 3(2019), 12 vom: 25. Juni, Seite 1815-1825 |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2019 |g number:12 |g day:25 |g month:06 |g pages:1815-1825 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2019000010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2019 |e 12 |b 25 |c 06 |h 1815-1825 | ||